Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Treatment-Resistant Depression (TRD)

Ibogaine for Treatment-Resistant Depression (TRD)

1 paper and 0 clinical trials exploring ibogaine as a treatment for treatment-resistant depression (trd).

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationAffects roughly a third of people with depression

Treatment-Resistant Depression (TRD)

Treatment-resistant depression, depression that has not responded to at least two adequate antidepressant trials, is where psychedelic and rapid-acting therapies are furthest along. Esketamine is FDA-approved, and in 2025 a synthetic psilocybin became the first classic psychedelic to meet a Phase 3 endpoint for depression. The progress is real, but so are the caveats: modest effect sizes, short-lived benefits, and unresolved questions about how well these trials are blinded.

Full Treatment-Resistant Depression (TRD) profile

Academic Research

1 paper
Paywallindividual

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.

Published
December 22, 2025
Journal
Addiction
Authors
Brett, J., Lea, T., Knock, E., Albert, S., Acheson, L., Siefried, K. J., Job, S.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Treatment-Resistant Depression (TRD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Treatment-Resistant Depression (TRD) trials Full Ibogaine profile Full Treatment-Resistant Depression (TRD) profile